0.125  0 (0%)		12-05 12:33
Open: 0.13 High: 0.13 Volume: 30		Pre. Close: 0.125 Low: 0.125 Market Cap: 7(M)

Short term
Mid term
Targets	6-month :	0.37	1-year :	0.41
Resists	First :	0.31	Second :	0.35
Pivot price	0.3
Supports	First :	0.25	Second :	0.21
MAs	MA(5) :	0.31	MA(20) :	0.31
	MA(100) :	0.35	MA(250) :	0.34
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	69.9	D(3) :	73.7
RSI	RSI(14): 44.8
52-week	High :	0.6	Low :	0.07

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ EMMA ] has closed above bottom band by 37.8%. Bollinger Bands are 34.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.3 - 0.3	0.3 - 0.3
Low:	0.25 - 0.26	0.26 - 0.26
Close:	0.3 - 0.3	0.3 - 0.3

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.

Tue, 14 Nov 2023
Emmaus Life Sciences sees strong Endari sales in MENA and US during 3Q - Proactive Investors UK

Tue, 14 Nov 2023
Emmaus Life Sciences Reports Q3 2023 Financial Results - PR Newswire

Wed, 23 Aug 2023
Emmaus Life Sciences Reports Management Changes - PR Newswire

Mon, 14 Aug 2023
Emmaus Life Sciences Reports Q2 2023 Financial Results - PR Newswire

Thu, 13 Jul 2023
Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman - PR Newswire

Mon, 15 May 2023
Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: PNK
Sector: Healthcare
Industry: Biotechnology
Shares Out	51 (M)
Shares Float	31 (M)
Held by Insiders	37.9 (%)
Held by Institutions	0 (%)
Shares Short	41 (K)
Shares Short P.Month	34 (K)

EPS	-0.21
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.69
Profit Margin	-57.8 %
Operating Margin	-35.9 %
Return on Assets (ttm)	-7.9 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	96.4 %
Gross Profit (p.s.)	0
Sales Per Share	0.36
EBITDA (p.s.)	-0.13
Qtrly Earnings Growth	0 %
Operating Cash Flow	-5 (M)
Levered Free Cash Flow	4 (M)

PE Ratio	-1.5
PEG Ratio	0
Price to Book value	-0.44
Price to Sales	0.83
Price to Cash Flow	-3.02

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	2019-07-17
Ex-Dividend Date	Invalid DateTime.